Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis

Systemic sclerosis (SSc) is an autoimmune disease with fibrosis of the skin and/or internal organs, causing a decrease in quality of life and survival. There is no causative therapy, and the pathophysiology of the SSc remains unclear. Studies showed that lipid metabolism was relevant for autoimmune...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marija Geroldinger-Simić, Thomas Bögl, Markus Himmelsbach, Norbert Sepp, Wolfgang Buchberger
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	systemic sclerosis lipidomics skin fibrosis lung fibrosis calcinosis cutis digital ulcers Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/87f8e91db1994fd79727dc576bf1909f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:87f8e91db1994fd79727dc576bf1909f
record_format	dspace
spelling	oai:doaj.org-article:87f8e91db1994fd79727dc576bf1909f2021-11-25T17:21:45ZChanges in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis10.3390/diagnostics111121162075-4418https://doaj.org/article/87f8e91db1994fd79727dc576bf1909f2021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4418/11/11/2116https://doaj.org/toc/2075-4418Systemic sclerosis (SSc) is an autoimmune disease with fibrosis of the skin and/or internal organs, causing a decrease in quality of life and survival. There is no causative therapy, and the pathophysiology of the SSc remains unclear. Studies showed that lipid metabolism was relevant for autoimmune diseases, but little is known about the role of lipids in SSc. In the present study, we sought to explore the phospholipid profile of SSc by using the lipidomics approach. We also aimed to analyze lipidomics results for different clinical manifestations of SSc. Experiments were performed using high-performance liquid chromatography coupled to mass spectrometry for the lipidomic profiling of plasma samples from patients with SSc. Our study showed, for the first time, significant changes in the level of phospholipids such as plasmalogens and sphingomyelins from the plasma of SSc patients as compared to controls. Phosphatidylcholine plasmalogens species and sphingomyelins were significantly increased in SSc patients as compared to controls. Our results also demonstrated a significant association of changes in the metabolism of phospholipids (phosphatidylcholine and phosphatidylethanolamine plasmalogens species and sphingomyelins) with different clinical manifestations of SSc. Further lipidomic studies might lead to the detection of lipids as new biomarkers or therapeutic targets of SSc.Marija Geroldinger-SimićThomas BöglMarkus HimmelsbachNorbert SeppWolfgang BuchbergerMDPI AGarticlesystemic sclerosislipidomicsskin fibrosislung fibrosiscalcinosis cutisdigital ulcersMedicine (General)R5-920ENDiagnostics, Vol 11, Iss 2116, p 2116 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	systemic sclerosis lipidomics skin fibrosis lung fibrosis calcinosis cutis digital ulcers Medicine (General) R5-920
spellingShingle	systemic sclerosis lipidomics skin fibrosis lung fibrosis calcinosis cutis digital ulcers Medicine (General) R5-920 Marija Geroldinger-Simić Thomas Bögl Markus Himmelsbach Norbert Sepp Wolfgang Buchberger Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis
description	Systemic sclerosis (SSc) is an autoimmune disease with fibrosis of the skin and/or internal organs, causing a decrease in quality of life and survival. There is no causative therapy, and the pathophysiology of the SSc remains unclear. Studies showed that lipid metabolism was relevant for autoimmune diseases, but little is known about the role of lipids in SSc. In the present study, we sought to explore the phospholipid profile of SSc by using the lipidomics approach. We also aimed to analyze lipidomics results for different clinical manifestations of SSc. Experiments were performed using high-performance liquid chromatography coupled to mass spectrometry for the lipidomic profiling of plasma samples from patients with SSc. Our study showed, for the first time, significant changes in the level of phospholipids such as plasmalogens and sphingomyelins from the plasma of SSc patients as compared to controls. Phosphatidylcholine plasmalogens species and sphingomyelins were significantly increased in SSc patients as compared to controls. Our results also demonstrated a significant association of changes in the metabolism of phospholipids (phosphatidylcholine and phosphatidylethanolamine plasmalogens species and sphingomyelins) with different clinical manifestations of SSc. Further lipidomic studies might lead to the detection of lipids as new biomarkers or therapeutic targets of SSc.
format	article
author	Marija Geroldinger-Simić Thomas Bögl Markus Himmelsbach Norbert Sepp Wolfgang Buchberger
author_facet	Marija Geroldinger-Simić Thomas Bögl Markus Himmelsbach Norbert Sepp Wolfgang Buchberger
author_sort	Marija Geroldinger-Simić
title	Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis
title_short	Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis
title_full	Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis
title_fullStr	Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis
title_full_unstemmed	Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis
title_sort	changes in plasma phospholipid metabolism are associated with clinical manifestations of systemic sclerosis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/87f8e91db1994fd79727dc576bf1909f
work_keys_str_mv	AT marijageroldingersimic changesinplasmaphospholipidmetabolismareassociatedwithclinicalmanifestationsofsystemicsclerosis AT thomasbogl changesinplasmaphospholipidmetabolismareassociatedwithclinicalmanifestationsofsystemicsclerosis AT markushimmelsbach changesinplasmaphospholipidmetabolismareassociatedwithclinicalmanifestationsofsystemicsclerosis AT norbertsepp changesinplasmaphospholipidmetabolismareassociatedwithclinicalmanifestationsofsystemicsclerosis AT wolfgangbuchberger changesinplasmaphospholipidmetabolismareassociatedwithclinicalmanifestationsofsystemicsclerosis
_version_	1718412483491790848

Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis

Ejemplares similares